Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 267

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 267
---
iamiR’s CLIA-certified laboratory. DiamiR has the capacity to process between about 3500 – 5500 tests per year. DiamiR plans on introducing automation and robots into its lab operations to increase capacity, reduce turn-around-time (TAT), improve efficiency, drive lower COGS, and reduce overhead expenses. DiamiR closely monitors FDA and congressional action around LDT statutes and will adjust its strategy accordingly. Drive early adoption of the tests based on establishing collaborations with leading academic centers and industrial partners to ensure strong support for the tests from Key Opinion Leaders (KOLs) at launch. DiamiR also aims to continue and to expand relationships with key associations, such as Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation (ADDF), Gates Ventures, and International Rett Syndrome Foundation (IRSF). DiamiR has participated in, and plans on attending and presenting our work at key symposiums and conferences, such as Alzheimer’s Association International Conference (AAIC), Clinical Trials on Alzheimer’s Disease (CTAD), AD/PD Alzheimer’s & Parkinson’s Diseases Conference, Child Neurology Society (CNS) meeting and publish its work in high profile peer-reviewed journals. Implement a robust commercial strategyaimed at securing coverage and contracting with Medicare and private payors. Publishing evidence of DiamiR’s tests’ validity and utility will drive its clinical work which in turn will power DiamiR’s reimbursement efforts. 160 Work closely with licensing and regulatory agenciesto ensure that clinical validity and utility of the tests satisfy all necessary requirements and quality control standards. These include maintaining licenses with States department of Health, CLIA and College of American Pathology (CAP). Build a pipeline/portfolio of early detection and risk assessment tests in Brain health and other indications,including tests for Rett syndrome, and gastrointestinal (GI) and pulmonary (lung) cancers. In addition to DiamiR’s CogniMIR test for AD, it is developing a miRNA-based assay for monitoring of progression and severity of Rett Syndrome; a panel of blood protein biomarkers for MCI and AD; a blood-based miRNA test for Glioblastoma, an aggressive form of brain cancer; and miRNA panels for lung and GI malignancies. The following table sets forth the current clinical status and next development steps for DiamiR’s current “lead products,” along with the date DiamiR currently believes it will complete such next step towards launching the tests in clinical practice setting.

| Product/Indication                        |